ZIF-8 nano material capable of covering erythrocyte membrane in targeting manner as well as preparation method and application of ZIF-8 nano material
By wrapping the red blood cell membrane on the ZIF-8 nanomaterial and connecting it with the Apt19S aptamer, the problem of its degradation and targeting in water is solved, the effects of targeted delivery and bone regeneration are achieved, and the drug carrier is improved Biosafety and efficacy.
Patent Information
- Application Number
- CN202411066308.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-05
AI Technical Summary
The existing ZIF-8 nanomaterials lack targeting in drug carrier applications, poor cell fusion and easy degradation in water, resulting in reduced efficacy.
By wrapping the ZIF-8 nanomaterial on the red blood cell membrane and connecting it with the Apt19S aptamer, nanomaterials with targeted coverage of the red blood cell membrane are prepared by membrane extrusion technology to enhance their biocompatibility and targeting performance.
Targeted delivery of ZIF-8 nanomaterials is achieved, promoting osteogenic differentiation and bone regeneration of bone marrow mesenchymal stem cells, and improving drug utilization and biosafety.
Smart Images

Figure CN119015439A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of material science and technology, and specifically relates to a ZIF-8 nano material with targeted red blood cell membrane coverage, a preparation method and an application thereof. Background Art
[0002] Metal organic framework (MOF) is a kind of crystalline material constructed by metal ions and organic frameworks. It has the characteristics of diverse structures, large specific surface area, uniform cavity, etc. MOF materials are widely used in catalysis, sensing and drug delivery. Among them, ZIF-8 is a kind of MOF with a large specific surface area and pore volume. It is an ideal drug carrier. Moreover, the Zn released in ZIF-8 2+ It can promote the osteogenic differentiation of bone marrow mesenchymal stem cells. However, the simple use of ZIF-8 as a drug carrier still has some defects, such as: no targeting ability, poor fusion with cells, easy degradation in water, thus reducing its efficacy.
[0003] With the maturity of cell membrane display technology, many materials are encapsulated in the cell membrane, thereby improving biosafety, prolonging blood circulation time, and enhancing fusion with cells. Red blood cells are the most abundant cells in the blood, and the red blood cell membrane is easy to obtain, has low immunogenicity, and maintains a stable structure. Integrating the two advantages of the red blood cell membrane function and the characteristics of ZIF-8 nanomaterials can achieve effective drug transportation.
[0004] However, further improvements are needed in the delivery and targeting of nanomaterials. Summary of the invention
[0005] The present invention aims to solve one of the technical problems in the related art to at least a certain extent. Targeted carriers can accurately deliver drugs to the target location, recruit specific cells to perform functions, and improve the utilization rate of drugs. Aptamers are short single-stranded nucleic acid sequences that can bind to target molecules. They have high affinity and specificity for specific targets and have been widely used in targeted drug delivery systems. Apt19S, as an aptamer, can recruit bone marrow mesenchymal stem cells to reach bone defects and promote their osteogenic differentiation. The present invention provides a ZIF-8 nanomaterial with targeted coverage of erythrocyte membranes, a preparation method and an application thereof. The provided nanomaterial has the effect of promoting osteogenic differentiation of bone marrow mesenchymal stem cells and bone regeneration.
[0006] Specifically, the technical solution provided by the present invention is as follows:
[0007] In a first aspect of the present invention, the present invention provides a nanomaterial with targeted coverage of erythrocyte membranes, comprising: a metal organic framework material, an erythrocyte membrane wrapped on the surface of the metal organic framework material, and an aptamer connected to the erythrocyte membrane;
[0008] The aptamer is Apt19S, and the metal organic framework material is ZIF-8.
[0009] The provided targeted nanomaterial covering the red blood cell membrane has low cytotoxicity, high biocompatibility, and is easier to enter the cells when co-cultured with bone marrow mesenchymal stem cells, and recruits more bone marrow mesenchymal stem cells to participate in osteogenic differentiation, further promoting bone regeneration. The provided nanomaterial has good stability and targeting performance, can specifically recruit bone marrow mesenchymal stem cells to participate in osteogenic differentiation, and can be used as a new nanomaterial to promote bone regeneration.
[0010] According to an embodiment of the present invention, the sequence of Apt19S is shown as SEQ ID NO:1.
[0011] According to an embodiment of the present invention, the aptamer is modified with cholesterol. According to an embodiment of the present invention, cholesterol may be modified at the 5' end of the aptamer.
[0012] According to an embodiment of the present invention, the average particle size of the metal organic framework material is 200-400nm. The average particle size of the metal organic framework material is 200-400nm, and the average particle size of the metal organic framework material after being wrapped by the red blood cell membrane is slightly increased, and the average particle size of the targeted red blood cell membrane-covering nanomaterial is 200nm-400nm.
[0013] In a second aspect of the present invention, there is provided a method for preparing the nanomaterial having targeted red blood cell membrane covering properties as described in the first aspect, comprising:
[0014] Extruding the metal organic framework material and the red blood cell membrane by membrane extrusion to obtain the metal organic framework material coated with the red blood cell membrane;
[0015] The aptamer and the metal organic framework material coated with the red blood cell membrane are mixed and incubated, and the free aptamer is removed to obtain the targeted nanomaterial covering the red blood cell membrane.
[0016] The provided method is based on metal organic framework materials, and uses membrane extrusion technology to coat the extracted red blood cell membrane on the surface of the metal organic framework material, and obtains a targeted nanomaterial covering the red blood cell membrane after modification with an aptamer. The preparation method is simple to operate, the synthesis equipment is simple, and the biocompatibility is high.
[0017] According to an embodiment of the present invention, the membrane extrusion is sequentially extruded through microporous membranes with pore sizes of 400 nm and 200 nm.
[0018] According to an embodiment of the present invention, the film extrusion is reciprocating extrusion 15 to 25 times.
[0019] According to an embodiment of the present invention, the metal organic framework material is a ZIF-8 solution, and the volume ratio of the ZIF-8 solution to the red blood cell membrane solution is 4:1.
[0020] According to an embodiment of the present invention, the volume ratio of the aptamer to the metal organic framework material coated with the red blood cell membrane is 1:200-240.
[0021] In a third aspect of the present invention, a targeted application of a nanomaterial covering red blood cell membrane in promoting osteogenic differentiation of bone marrow mesenchymal stem cells and bone regeneration is provided.
[0022] According to a specific embodiment, the targeted nanomaterial covering the red blood cell mill is used as a carrier of bone marrow mesenchymal stem cells.
[0023] The beneficial effects achieved by the present invention include at least:
[0024] (1) The ZIF-8 nanomaterial with targeted coverage of erythrocyte membranes of the present invention has a uniform nanostructure, is easy to operate, and has high biosafety. The Zn released by the ZIF-8 metal organic framework material 2+ It can promote osteogenic differentiation of mesenchymal stem cells and bone regeneration.
[0025] (2) The nanomaterial with targeted coverage of erythrocyte membranes described in the present invention uses erythrocyte membranes to cover metal organic framework materials, thereby enhancing compatibility with cell membranes and promoting more material to be taken up by cells; maintaining structural integrity and reducing drug leakage.
[0026] (3) The nanomaterial with targeted coverage of red blood cell membranes described in the present invention is connected to an aptamer targeting mesenchymal stem cells, which can specifically recruit bone marrow mesenchymal stem cells to exert osteogenic differentiation function.
[0027] (4) The nanomaterial with targeted coverage of red blood cell membranes described in the present invention can be used as a carrier to improve material properties, accurately target bone defect areas, and promote bone regeneration. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 This is a transmission electron microscopy image of ZIF-8@RM-Apt prepared according to Example 1 of the present invention.
[0029] Figure 2 Graph showing the particle size distribution of ZIF-8 and ZIF-8@RM-Apt prepared according to Example 1 of the present invention.
[0030] Figure 33 is the potential distribution diagram of ZIF-8, RM and ZIF-8@RM-Apt prepared according to Example 1 of the present invention.
[0031] Figure 4 This is a fluorescence confocal microscopy image of ZIF-8@RM-Apt prepared in Example 1 of the present invention after co-culture with bone marrow mesenchymal stem cells.
[0032] Figure 5 The CCK-8 test results after co-culturing ZIF-8 and ZIF-8@RM-Apt prepared in Example 1 of the present invention with bone marrow mesenchymal stem cells.
[0033] Figure 6 The ALP staining results after osteogenic induction of bone marrow mesenchymal stem cells using ZIF-8 and ZIF-8@RM-Apt prepared in Example 1 of the present invention. DETAILED DESCRIPTION
[0034] Embodiments of the present invention are described in detail below. Examples of the embodiments are shown in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are exemplary and are intended to be used to explain the present invention, but should not be construed as limiting the present invention.
[0035] The present invention provides a targeted nanomaterial covering an erythrocyte membrane, comprising: a metal organic framework material, an erythrocyte membrane wrapped on the surface of the metal organic framework material, and an aptamer connected to the erythrocyte membrane;
[0036] The aptamer is Apt19S, and the metal organic framework material is ZIF-8.
[0037] The aptamer Apt19S used is specifically used to recognize and bind to mesenchymal stem cells. Its binding rate with various non-stem cells is low, and it can be used to study the specific binding and directional recruitment of stem cells. ZIF-8 is a metal organic framework material with good biocompatibility and low cytotoxicity. The released Zn 2+ It can promote osteogenesis. The erythrocyte membrane is not immunogenic, can maintain the stability of the internal material, and enhance the fusion with the cell membrane. The targeted nanomaterial covering the erythrocyte membrane provided by this method has low cytotoxicity, high biocompatibility, and is easier to enter the cells when co-cultured with bone marrow mesenchymal stem cells, and can recruit more bone marrow mesenchymal stem cells to participate in osteogenic differentiation, further promoting bone regeneration.
[0038] According to a specific embodiment, the sequence of Apt19S is shown as SEQ ID NO:1.
[0039] The sequence shown in SEQ ID NO: 1 is as follows:
[0040] AGGTCAGATGAGGAGGGGGACTTAGGACTGGGTTTATGACCTATGCGTG(5'—3')
[0041] (SEQ ID NO:1)
[0042] According to a specific embodiment, the aptamer is modified with cholesterol. Considering that the red blood cell membrane is a lipid structure, the aptamer modified with cholesterol can be more conducive to the connection between the aptamer and the red blood cell membrane, and the connection efficiency is better than other modifications.
[0043] The present invention also provides a method for preparing the ZIF-8 nanomaterial having targeted coverage of erythrocyte membranes as described above, comprising:
[0044] Extruding the metal organic framework material and the red blood cell membrane by membrane extrusion to obtain the metal organic framework material coated with the red blood cell membrane;
[0045] The aptamer and the metal organic framework material coated with the red blood cell membrane are mixed and incubated, and the free aptamer is removed to obtain the targeted nanomaterial covering the red blood cell membrane.
[0046] According to a specific embodiment, the membrane extrusion is sequentially extruded through microporous membranes with pore sizes of 400 nm and 200 nm.
[0047] According to a specific embodiment, the film extrusion is reciprocating extrusion 15 to 25 times, for example, 20 times.
[0048] According to a specific embodiment, the metal organic framework material is a ZIF-8 solution, and the volume ratio of the ZIF-8 solution to the erythrocyte membrane is 4: 1. It was found during the study that when the amount of the ZIF-8 solution is too much, there will be more ZIF-8 particles that are not coated by the erythrocyte membrane; when the amount of the erythrocyte membrane is too much, there will be more erythrocyte membranes that are not coated with ZIF-8 particles scattered in the material. It was found through transmission electron microscopy that when there is a suitable concentration ratio, the ZIF-8 particles and the erythrocyte membrane will be more fully utilized and coated, otherwise there will be more remaining ZIF-8 or erythrocyte membranes, thereby affecting the quality of the prepared nanomaterial with targeted coverage of the erythrocyte membrane. And because there are too many ZIF-8 or erythrocyte membranes, they need to be removed specifically, making the preparation process more complicated and increasing the difficulty.
[0049] The aptamer mentioned is provided in the form of an aptamer solution. According to a specific embodiment, the volume ratio of the aptamer to the metal-organic framework material coated with the erythrocyte membrane is 1:200-240. When the aptamer content is too much, the aptamer that cannot bind to the metal-organic framework material coated with the erythrocyte membrane will exist in the solution in a free manner and can be removed after washing. When the aptamer content is too little, some metal-organic framework materials coated with the erythrocyte membrane cannot fully bind to the aptamer, and the efficiency is low. In our experiment, the aptamers synthesized according to the sequence will have a concentration and a recommended amount, which can meet the requirements of fully binding to the erythrocyte membrane without too much waste. Erythrocyte membrane coating will increase the particle size of the metal-organic framework to a certain extent. Under this ratio condition, a nanomaterial with a suitable volume and targeted coverage of the erythrocyte membrane can be obtained, and a better biological effect can be achieved, which has little effect on the transport and release of the nanomaterial in the cell.
[0050] According to a specific embodiment, the ZIF-8 solution is obtained by resuspending ZIF-8 particles in distilled water and ultrasonically dispersing them. The ZIF-8 particles are obtained by mixing 2-methylimidazole and zinc nitrate hexahydrate, stirring, centrifuging the obtained suspension, and collecting white precipitated particles.
[0051] According to a specific embodiment, the molar ratio of the zinc nitrate hexahydrate to the 2-methylimidazole is 1:(20-24). If the molar ratio of the zinc nitrate hexahydrate to the 2-methylimidazole is too high or too low, the properties of the obtained material will change, such as failure to nucleate to obtain a suspension, too small or too large particle size, color mismatch, etc.
[0052] According to a specific embodiment, the incubation is carried out at 4 degrees Celsius for 10 to 20 hours. After the incubation, the aptamer is removed by centrifugation at a speed of 5000 to 10000 rpm.
[0053] According to a specific embodiment, the solution of red blood cell membranes is obtained by the following method:
[0054] After the blood is collected from the animal, a series of centrifugation processes are performed, and the obtained white precipitate is dissolved in a buffer solution to obtain a red blood cell membrane solution. The volume ratio of the blood collected from the animal to the red blood cell membrane solution is 6-7:1.
[0055] The animal mentioned is rat, and the sequence of Apt19S used is the sequence shown in SEQ ID NO: 1. The present invention also provides a use of a targeted nanomaterial covering erythrocyte membrane in the preparation of a material for promoting osteogenic differentiation of bone marrow mesenchymal stem cells and bone regeneration.
[0056] According to a specific embodiment, the provided targeted erythrocyte membrane-covering nanomaterial may be a ZIF-8 nanomaterial covering the erythrocyte membrane, which is connected to an Apt19S aptamer and can be used as a carrier of bone marrow mesenchymal stem cells.
[0057] The present invention co-cultures the targeted nanomaterial covering the red blood cell membrane with bone marrow mesenchymal stem cells to observe the targeting and osteogenesis effects, and uses a random sequence aptamer (Random Apt) as a control. The experimental results show that Apt19S has stronger targeting.
[0058] The ZIF-8 material is coated with erythrocyte membrane, which is easy to obtain and has low immunogenicity. The coating has little effect on the volume of the material. Compared with other membrane materials, such as bone marrow mesenchymal stem cell membrane, there will be no problems such as the difficulty in controlling the extraction efficiency and amount and the large volume of the membrane.
[0059] ZIF-8 material, due to its strong loading capacity and high biocompatibility, can release Zn 2+ , which has been used in many ways. The present invention coats the erythrocyte membrane on the ZIF-8 material, and connects it to the cholesterol-affinity Apt19S sequence according to its characteristics, thereby overcoming the problems of easy degradation, insufficient targeting, and low efficiency. The provided targeted erythrocyte membrane-covered nanomaterial can be used as a carrier to accurately target the bone defect area and promote bone regeneration.
[0060] The protection scheme of the present invention is described below by specific examples. It should be noted that these examples are only used to facilitate the understanding of those skilled in the art and should not be regarded as limiting the scope of protection of the present invention. Unless otherwise specified, the reagents used in the examples can be obtained commercially. The prepared targeted nanomaterial covering the erythrocyte membrane is replaced by the number "ZIF-8@RM-Apt".
[0061] Example 1
[0062] Example 1: The targeted red blood cell membrane-covering nanomaterial ZIF-8@RM-Apt was prepared by the following method.
[0063] (1) Preparation of ZIF-8 nanomaterials:
[0064] First, 65.6 mg of 2-methylimidazole was dissolved in 0.5 mL of distilled water to obtain a 2-methylimidazole solution; 11.88 mg of zinc nitrate hexahydrate was dissolved in 0.5 mL of distilled water to prepare a zinc nitrate hexahydrate solution. The zinc nitrate hexahydrate solution was slowly dripped into the 2-methylimidazole solution, stirring throughout the process; after stirring at room temperature for 4 hours, the obtained milky white suspension was transferred to a centrifuge tube. Centrifuge at 10,000 rpm for 10 minutes in a centrifuge, discard the supernatant, add distilled water and centrifuge three times to collect the white precipitate particles of ZIF-8.
[0065] (2) Extraction of red blood cell membrane:
[0066] After 5 rats were anesthetized by intraperitoneal injection of sodium pentobarbital, blood was collected from the abdominal aorta under negative pressure into anticoagulant tubes containing citrate anticoagulant, a total of 4 tubes, each tube 8mL, and centrifuged at 4000rpm for 20 minutes after balancing, and the supernatant and the middle layer of white fluffy material were discarded. The lower red precipitate was resuspended with 3 times the volume of pre-cooled PBS, centrifuged at 4000rpm for 20 minutes and the supernatant was discarded, and repeated 3 times. Then, the lower red precipitate was resuspended with 40 times the volume of Tris-HCl (10mM, pH7.4), and allowed to stand at 4℃ for 1.5 hours. After centrifugation at 9000rpm for 20 minutes, the supernatant was discarded. Then, the white precipitate was resuspended with pre-cooled PBS, and the supernatant was discarded after ultracentrifugation at 9000rpm for 20 minutes, and repeated 3 times. The final white precipitate is the red blood cell membrane, which is collected in a 15mL centrifuge tube with 5mL PBS for standby use.
[0067] (3) Preparation of ZIF-8 nanomaterials covering red blood cell membranes:
[0068] The ZIF-8 particles obtained in step (1) were resuspended in 1200 μL of distilled water, and then ultrasonically dispersed and mixed with 300 μL of red blood cell membrane obtained in step (2). The particles were squeezed through microporous membranes with pore sizes of 400 nm and 200 nm in sequence using a membrane squeezer, and the mixture was squeezed back and forth 20 times to obtain a ZIF-8 material coated with red blood cell membrane.
[0069] (4) Preparation of aptamer-linked ZIF-8 nanomaterials covering red blood cell membranes ZIF-8@RM-Apt:
[0070] 5 μL of cholesterol-modified aptamer solution was added dropwise to the ZIF-8 covering the red blood cell membrane obtained in step (3), incubated at 4 degrees Celsius for 12 hours, centrifuged at 5000 rpm for 5 minutes to remove free aptamers, washed three times by centrifugation with distilled water, and ZIF-8@RM-Apt was collected.
[0071] The transmission electron microscopy image of the prepared ZIF-8@RM-Apt is shown in Figure 1 As shown, the results show that ZIF-8@RM-Apt has a hexahedral structure and the outer layer is wrapped by a membrane structure.
[0072] The particle size distribution of the prepared ZIF-8 and ZIF-8@RM-Apt is shown in Figure 2 As shown, the results show that the particle size gradually increases from ZIF-8 to ZIF-8@RM-Apt, and the particle size of ZIF-8@RM-Apt is about 270nm.
[0073] The potential distribution diagrams of the prepared ZIF-8, RM red blood cell membrane and ZIF-8@RM-Apt are shown in Figure 3 As shown, the results show that the potential of ZIF-8 is approximately 19 mV, the potential of RM red blood cell membrane is approximately -31 mV, and the potential of ZIF-8@RM-Apt is approximately -26 mV.
[0074] 1×10 5 Rat bone marrow mesenchymal stem cells were inoculated on a 15 mm diameter cell slide and cultured in a 37°C incubator for 12 hours. Then, 10 μL of ZIF-8@RM-Apt with red fluorescent dye was added to the cells for co-culture, where Aptamer could be Random-Apt or Apt19S. After co-culture in a 37°C incubator for 6 hours, the cells were rinsed with distilled water three times, fixed with 4% paraformaldehyde, stained with DAPI nuclei, stained with DIO dye for cell membranes, and photographed with confocal microscopy.
[0075] Fluorescence confocal microscopy results Figure 4 As shown, ZIF-8@RM-Apt co-localizes with cells and can enter the cytoplasm. The sequence of the aptamer Aptamer is a random sequence (Random-Apt, the random sequence is the control sequence, the length is consistent with Apt19S, and the sequence is an arbitrary sequence) or a sequence targeted by mesenchymal stem cells (Apt19S). In the figure, green represents the bone marrow mesenchymal stem cell membrane, red represents the aptamer, and blue represents the cell nucleus. Through the co-localization image, it can be concluded that the material of the Apt19S group can be taken up by bone marrow mesenchymal stem cells after 6 hours of co-culture, while the material of the Random-Apt group is still around the cells.
[0076] Example 2
[0077] Example 2 evaluated the cytotoxicity of the prepared ZIF-8@RM-Apt material, including the following contents:
[0078] 1×10 5Rat bone marrow mesenchymal stem cells were inoculated into a 12-well plate and cultured in an incubator at 37°C for 12 hours. Then, 10 μL of ZIF-8 and ZIF-8@RM-Apt were added to the cells for co-culture. The cell culture medium was replaced and ZIF-8 and ZIF-8@RM-Apt materials were added again every two days. The CCK-8 kit (manufacturer: MCE, China) was used to detect cell activity on the 1st, 3rd, and 5th days of co-culture.
[0079] Results Figure 5 As shown, ZIF-8 and ZIF-8@RM-Apt showed no obvious cytotoxicity and had high biosafety.
[0080] Example 3
[0081] Example 3 evaluates the effect of the prepared material on the osteogenic differentiation of bone marrow mesenchymal stem cells, including the following contents:
[0082] 1×10 5 Rat bone marrow mesenchymal stem cells were inoculated into a 12-well plate and cultured in an incubator at 37°C for 12 hours. Then, 10 μL of ZIF-8 and ZIF-8@RM-Apt were added to the cells for co-culture. The medium and materials were changed every two days. After culturing in osteogenic induction medium for 7 days, the cells were rinsed with distilled water for 3 times, fixed with 4% paraformaldehyde, and stained with an ALP staining kit (manufacturer: Beyotime, China).
[0083] Results Figure 6 As shown, both ZIF-8 and ZIF-8@RM-Apt can promote the osteogenic differentiation of bone marrow mesenchymal stem cells, and ZIF-8@RM-Apt has a stronger effect.
[0084] The material provided by the present invention can be used to promote osteogenic differentiation of bone marrow mesenchymal stem cells. By co-culturing ZIF-8@RM-Apt with bone marrow mesenchymal stem cells, more cells can be targeted to participate in osteogenic differentiation. The fusion between cell membranes is conducive to the uptake of ZIF-8 particles by bone marrow mesenchymal stem cells. 2+ The release of can further promote osteogenic differentiation. Therefore, the present invention can be used as a targeted drug delivery system to enhance the osteogenic differentiation of bone marrow mesenchymal stem cells and has great potential to promote bone regeneration.
[0085] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "specific implementation methods", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification and the features of different embodiments or examples without contradiction.
[0086] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A nanomaterial with targeted coverage of red blood cell membranes, characterized in that: include: A metal organic framework material, an erythrocyte membrane wrapped on the surface of the metal organic framework material, and an aptamer connected to the erythrocyte membrane; The aptamer is Apt19S, The metal organic framework material is ZIF-8.
2. The nanomaterial with targeted coverage of red blood cell membrane according to claim 1, characterized in that: The sequence of Apt19S is shown in SEQ ID NO:
1.
3. The nanomaterial with targeted coverage of red blood cell membrane according to claim 1, characterized in that: The aptamer has a cholesterol modification.
4. The nanomaterial with targeted coverage of red blood cell membrane according to claim 1, characterized in that: The average particle size of the metal organic framework material is 200 to 400 nm; The average particle size of the targeted nanomaterial covering the red blood cell membrane is 200nm-400nm.
5. A method for preparing the nanomaterial with targeted red blood cell membrane coverage according to any one of claims 1 to 4, characterized in that: include: Extruding the metal organic framework material and the red blood cell membrane by membrane extrusion to obtain the metal organic framework material coated with the red blood cell membrane; The aptamer and the metal organic framework material coated with the red blood cell membrane are mixed and incubated, and the free aptamer is removed to obtain the nano material with targeted coverage of the red blood cell membrane.
6. The method according to claim 5, characterized in that The membrane extrusion is sequentially extruded through microporous membranes with pore sizes of 400 nm and 200 nm; Optionally, the film extrusion is reciprocating extrusion 15 to 25 times.
7. The method according to claim 5, characterized in that The metal organic framework material is a ZIF-8 solution, and the volume ratio of the ZIF-8 solution to the red blood cell membrane solution is 4:
1.
8. The method according to claim 5, characterized in that The aptamer is prepared as an aptamer solution, and the volume ratio of the aptamer solution to the metal organic framework material coated with the red blood cell membrane is 1:200-240.
9. Use of the nanomaterial with targeted coverage of erythrocyte membrane according to any one of claims 1 to 4 in promoting osteogenic differentiation of bone marrow mesenchymal stem cells and bone regeneration.
10. The use according to claim 9, characterized in that: The nano material with targeted coverage of red blood cell membrane is used as a carrier of bone marrow mesenchymal stem cells.
Citation Information
Patent Citations
Bionic nano-carrier with dual functions of oxidation and anti-oxidation, and preparation method and application thereof
CN111000825A
Titanium-based active bone implant with ROS response and preparation method of implant
CN111420118A
Metal organic framework composite nanomaterial with targeting property and pH responsiveness as well as preparation method and application of metal organic frame composite nanomaterial
CN111643480A
Nucleic acid aptamer delivery vector and preparation method and application thereof
CN112168973A
Distribution box management system
KR102555049B1
Cited By
Targeting nanometer material covering erythrocyte membrane as well as preparation method and application thereof
CN119679964A
